Credit Suisse Group reiterated their hold rating on shares of Roche (OTCMKTS:RHHVF) in a research note published on Wednesday morning, AnalystRatings.com reports.
RHHVF has been the topic of several other reports. Redburn Partners upgraded Roche to a buy rating in a research report on Wednesday, April 1st. JPMorgan Chase & Co. restated a buy rating on shares of Roche in a research report on Thursday, June 25th. HSBC upgraded Roche to a hold rating in a report on Thursday, April 30th. Goldman Sachs Group reiterated a buy rating on shares of Roche in a report on Monday, July 13th. Finally, Deutsche Bank reiterated a buy rating on shares of Roche in a report on Tuesday, April 7th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Roche has an average rating of Buy.
OTCMKTS:RHHVF opened at $342.50 on Wednesday. Roche has a 12-month low of $265.67 and a 12-month high of $399.00. The stock’s fifty day simple moving average is $352.98 and its 200-day simple moving average is $340.62.
Roche Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Further Reading: Do stock splits help investors?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.